Fig. 1.
Fig. 1. Schematic representation of protocols LSA2L2 , AIEOP 8703, 9102, and 9103. Shaded areas indicate the time (in weeks) of marrow sampling. ADR, adriamycin; ARA-C, cytarabine; PDN, prednisone; CF, citrovorum factor; 6-MP, 6-mercaptopurine; CPM, cyclophosphamide; MTX, methotrexate; DNM, daunorubicin; RT, radiotherapy; DMZ, dexamethasone; 6-TG, 6-thioguanine; HD, high-dose; IT, intrathecal; TIT, triple IT therapy (PDN, ARA-C, MTX); HD-L-ASP, high-dose L-asparaginase; VCR, vincristine; VM-26, teniposide; VP-16, etoposide; L-ASP, L-asparaginase. B1, block 1 (6-MP, DMZ, VCR, HD-MTX, HD-ARA-C, HD-L-ASP, and TIT); B2, block 2 (6-TG, DMZ, VDS, HD-MTX, DNM, CPM, HD-L-ASP, and TIT); B3, block 3 (DMZ, VP-16, HD-ARA-C, HD-L-ASP, and TIT).

Schematic representation of protocols LSA2L2 , AIEOP 8703, 9102, and 9103. Shaded areas indicate the time (in weeks) of marrow sampling. ADR, adriamycin; ARA-C, cytarabine; PDN, prednisone; CF, citrovorum factor; 6-MP, 6-mercaptopurine; CPM, cyclophosphamide; MTX, methotrexate; DNM, daunorubicin; RT, radiotherapy; DMZ, dexamethasone; 6-TG, 6-thioguanine; HD, high-dose; IT, intrathecal; TIT, triple IT therapy (PDN, ARA-C, MTX); HD-L-ASP, high-dose L-asparaginase; VCR, vincristine; VM-26, teniposide; VP-16, etoposide; L-ASP, L-asparaginase. B1, block 1 (6-MP, DMZ, VCR, HD-MTX, HD-ARA-C, HD-L-ASP, and TIT); B2, block 2 (6-TG, DMZ, VDS, HD-MTX, DNM, CPM, HD-L-ASP, and TIT); B3, block 3 (DMZ, VP-16, HD-ARA-C, HD-L-ASP, and TIT).

Close Modal

or Create an Account

Close Modal
Close Modal